Harvey Levy, MD
Senior Physician in Medicine, Division of Genetics and Genomics
Professor of Pediatrics, Harvard Medical School
Image
Harvey Levy, MD
Senior Physician in Medicine, Division of Genetics and Genomics
Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
Medical College of Georgia
1960
Augusta
GA
Internship
Boston City Hospital
1961
Boston
MA
Residency
Columbia-Presbyterian Medical Center
1962
New York
NY
Residency
Johns Hopkins Hospital
1965
New York
NY
Residency
Boston City Hospital
1966
Boston
MA
Fellowship
Massachusetts General Hospital
1968
Boston
MA
Certifications
American Board of Medical Genetics and Genomics (Clinical Biochemical Genetics)
American Board of Pediatrics (General)
Publications
Safety and efficacy of pegtibatinase enzyme replacement therapy in adults with classical homocystinuria in the COMPOSE® phase 1/2 randomized trial. View Abstract
Past as Prologue: Predicting Potential Psychosocial-Ethical Burdens of Positive Newborn Screens as Conditions Propagate. View Abstract
The treatment of biochemical genetic diseases: From substrate reduction to nucleic acid therapies. View Abstract
Classical phenylketonuria presenting as maternal PKU syndrome in the offspring of an intellectually normal woman. View Abstract
In memoriam: Charles Robert Scriver, CM, CC, GOQ, FRS, FRSC (1930-2023). View Abstract
Is More Effective Newborn Screening for Homocystinuria on the Horizon? View Abstract
The hypergonadotropic hypogonadism conundrum of classic galactosemia. View Abstract
Charles Scriver: Epitome of the physician scientist. View Abstract
Early Development of Newborn Screening for HCU and Current Challenges. View Abstract
Pancreatic involvement in patients with inborn errors of metabolism. View Abstract
Robert Guthrie and the Trials and Tribulations of Newborn Screening. View Abstract
Ethical and Psychosocial Implications of Genomic Newborn Screening. View Abstract
The Genetic Landscape and Epidemiology of Phenylketonuria. View Abstract
Discontinuation of Pegvaliase therapy during maternal PKU pregnancy and postnatal breastfeeding: A case report. View Abstract
Can Newborn Screening for Vitamin B12 Deficiency be Incorporated into All Newborn Screening Programs? View Abstract
Phenylalanine hydroxylase genotype-phenotype associations in the United States: A single center study. View Abstract
Phenotypic variability in deficiency of the a subunit of succinate-CoA ligase. View Abstract
The ability of an LC-MS/MS-based erythrocyte GALT enzyme assay to predict the phenotype in subjects with GALT deficiency. View Abstract
Revising the Psychiatric Phenotype of Homocystinuria. View Abstract
Untargeted metabolomics identifies unique though benign biochemical changes in patients with pathogenic variants in UROC1. View Abstract
The BabySeq project: implementing genomic sequencing in newborns. View Abstract
Phenylalanine ammonia lyase (PAL): From discovery to enzyme substitution therapy for phenylketonuria. View Abstract
Acute Illness Protocol for Urea Cycle Disorders. View Abstract
Metabolomic Markers of Essential Fatty Acids, Carnitine, and Cholesterol Metabolism in Adults and Adolescents with Phenylketonuria. View Abstract
Acute Illness Protocol for Maple Syrup Urine Disease. View Abstract
Metabolomic Insights into the Nutritional Status of Adults and Adolescents with Phenylketonuria Consuming a Low-Phenylalanine Diet in Combination with Amino Acid and Glycomacropeptide Medical Foods. View Abstract
Dietary amino acid intakes associated with a low-phenylalanine diet combined with amino acid medical foods and glycomacropeptide medical foods and neuropsychological outcomes in subjects with phenylketonuria. View Abstract
Metabolomic changes demonstrate reduced bioavailability of tyrosine and altered metabolism of tryptophan via the kynurenine pathway with ingestion of medical foods in phenylketonuria. View Abstract
Acute Illness Protocol for Fatty Acid Oxidation and Carnitine Disorders. View Abstract
Acute Illness Protocol for Organic Acidemias: Methylmalonic Acidemia and Propionic Acidemia. View Abstract
Long-term outcome of expanded newborn screening at Boston children's hospital: benefits and challenges in defining true disease. View Abstract
Confounding factors in identification of disease-resilient individuals. View Abstract
Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial. View Abstract
The remarkable S. Harvey Mudd - A reminiscence. View Abstract
Hyperphenylalaninemia and the genomic revolution. View Abstract
Adherence to tetrahydrobiopterin therapy in patients with phenylketonuria. View Abstract
The complexity of newborn screening follow-up in phenylketonuria. View Abstract
Management of a Woman With Maple Syrup Urine Disease During Pregnancy, Delivery, and Lactation. View Abstract
Phenylketonuria Scientific Review Conference: state of the science and future research needs. View Abstract
Newborn screening: the genomic challenge. View Abstract
Genomics in newborn screening. View Abstract
Is melatonin synthesis a new biomarker for the pathogenesis and treatment of phenylketonuria? View Abstract
Congenital heart disease in maternal PKU. View Abstract
A germline or de novo mutation in two families with Gaucher disease: implications for recessive disorders. View Abstract
The adult galactosemic phenotype. View Abstract
Newborn screening conditions: What we know, what we do not know, and how we will know it. View Abstract
Phenylketonuria. View Abstract
Sudden death in medium chain acyl-coenzyme a dehydrogenase deficiency (MCADD) despite newborn screening. View Abstract
Newborn screening of lysosomal storage disorders. View Abstract
Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. View Abstract
Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. View Abstract
Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. View Abstract
Mutations in the phenylalanine hydroxylase gene identified in 95 patients with phenylketonuria using novel systems of mutation scanning and specific genotyping based upon thermal melt profiles. View Abstract
Pericardial effusion in primary systemic carnitine deficiency. View Abstract
Newborn screening for metabolic disorders. View Abstract
Subacute combined degeneration of the spinal cord in cblC disorder despite treatment with B12. View Abstract
The use of betaine in the treatment of elevated homocysteine. View Abstract
The clinical aspects of newborn screening: importance of newborn screening follow-up. View Abstract
Fetal fatty acid oxidation defects and maternal liver disease in pregnancy. View Abstract
Metabolic disorders in the center of genetic medicine. View Abstract
Krabbe disease: severe neonatal presentation with a family history of multiple sclerosis. View Abstract
Brief report: Predictors of parenting stress among parents of children with biochemical genetic disorders. View Abstract
Expanded screening of newborns for genetic disorders. View Abstract
Historical background for the maternal PKU syndrome. View Abstract
Research design, organization, and sample characteristics of the Maternal PKU Collaborative Study. View Abstract
The Maternal Phenylketonuria International Study: 1984-2002. View Abstract
Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome. View Abstract
Pregnancy experiences in the woman with mild hyperphenylalaninemia. View Abstract
Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. View Abstract
Lessons from the past--looking to the future. Newborn screening. View Abstract
Molecular genetic and potential biochemical characteristics of patients with T-protein deficiency as a cause of glycine encephalopathy (NKH). View Abstract
Infantile hypermethioninemia and hyperhomocysteinemia due to high methionine intake: a diagnostic trap. View Abstract
Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema. View Abstract
Expanded newborn screening using tandem mass spectrometry. View Abstract
Neonatal screening for medium--chain acyl-CoA dehydrogenase deficiency. View Abstract